Zyversa Therapeutics Inc (ZVSA)
ZyVersa Therapeutics Inc. (OTC: ZVSA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for renal and inflammatory diseases. Its pipeline includes Cholesterol Efflux Mediator VAR 200, an injectable candidate in Phase 2a testing for renal indications such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. The company also is developing Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody in preclinical development for a range of inflammatory and related conditions, including acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson’s disease, Huntington’s disease, atherosclerosis, Alzheimer’s disease, and obesity. ZyVersa Therapeutics has licensing agreements with L&F Research LLC and InflamaCORE, LLC. The company was founded in 2014 and is based in Weston, Florida.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-ZVSA
|
$0.15
|
27.1% Upside
|
Undervalued
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 7, 2026
|
0.0x
|
-0.1x
|
—
|
931.03 K
|
1.828 M
|
56.3%
|
94.8%
|
-312.4
|
—
|
16.9%
|
